Conversation: 165 Britain and America’s poor state of health may benefit Medavisor’s push to be a global player.

There is no shortage of free apps to help you connect with your pharmacy to allow you to order your latest medication, or for that matter, remind you to take it.

But the CEO of Medadvisor [ASX:RMD], which is just such an app, says they are different.

Here are some of the reasons he believes this is so:

• App use leads to around 20% improved compliance of taking and following medication recommended by health professionals.

• Better compliance leads to increased revenue for both the drug company and the dispensing pharmacist.

• Drug companies pay Medadvisor per app user and provide significant content that Medadvisor algorithms use to drip feed valuable information to patients at appropriate times.

• Two USA deals will see a different revenue model where MedAdvisor gets paid per message sent to a patient and one of its new American partners sent out 865 million messages last year.

According to Robert Read, CEO of Medadvisor, the app, either directly, or as a white label, which allows companies like Amcal to claim it as their own, has a 60% penetration of the Australian market.

In our recent Conversation Read told me that the knowledge and experience they have gained in the Australian market has led them to confidently start tackling global markets like the United States, UK and South East Asia.

MedAdvisor has struck two new deals in the United States, been endorsed by a major UK pharmacy body and signed a 50/50 joint venture with a major South East Asian pharmacy chain.